Motif Bio PLC Replay for Analyst & Investor Conference Call
25 Aprile 2016 - 8:01AM
RNS Non-Regulatory
TIDMMTFB
Motif Bio PLC
25 April 2016
Motif Bio plc
("Motif" or the "Company")
Analyst & Investor conference call
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical
company specialising in developing novel antibiotics, announces
that following the conference call for analysts and investors that
took place on Wednesday 20 April 2016 a playback facility is
available until Wednesday 4 May 2016. Dial-in details for the
replay are below:
Please dial: 0121 260 4861 (UK)
1 866 268 1947 (US)
+44 121 260 4861 (All other locations)
Passcode: 3110627 (followed by #)
In call instructions
Press 1 Play Recording
Press 2 Stop Recording
Press 4 Rewind Recording
Press 5 Pause Recording
Press 6 Fast Forward Recording
Press 0 Repeat Instructions / Options Menu
Questions were submitted to the Company via email following the
call and these and their answers are available on the Company
website: http://www.motifbio.com/conference-call-q-a/
For further information please contact:
Motif Bio plc info@motifbio.com
Graham Lumsden (Chief Executive
Officer)
Zeus Capital Limited (NOMAD &
BROKER)
Phil Walker/Dan Bate
Dominic Wilson +44 (0)20 3829 5000
Northland Capital Partners Limited
(BROKER)
Patrick Claridge/ David Hignell
John Howes/ Rob Rees (Broking) +44 (0)20 3861 6625
Walbrook PR Ltd. (FINANCIAL PR +44 (0)20 7933 8780 or motifbio@walbrookpr.com
& IR) Mob: +44 (0)7980 541 893
Paul McManus Mob: +44 (0)7900 608 002
Mike Wort
MC Services AG (EUROPEAN IR)
Raimund Gabriel +49 (0)89 210 2280
Notes to Editors:
Motif is a clinical-stage biopharmaceutical company,
specialising in the development of novel antibiotics that are
designed to be effective against serious and life-threatening
infections caused by multi-drug resistant bacteria. Our lead
product candidate, iclaprim, is being developed for the treatment
of the most common and serious bacterial infections such as acute
bacterial skin and skin structure infections (ABSSSI) and hospital
acquired bacterial pneumonia (HABP), including those caused by
resistant strains such as MRSA (methicillin-resistant
Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on
track to be completed in 2017 and if approved, iclaprim could be
ready for commercialization in 2018. The Company is in discussions
with pharmaceutical companies and universities to build a pipeline
of innovative antibiotics targeting Gram-positive and Gram-negative
bacteria. For additional information about Motif please visit
www.motifbio.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPGUQUCUPQGRP
(END) Dow Jones Newswires
April 25, 2016 02:01 ET (06:01 GMT)
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a Motif Bio Plc (Borsa di Londra): 0 articoli recenti
Più Motif Bio Articoli Notizie